Dosage & Administration Drug label Prior authorization Financial assistance

Enspryng

(satralizumab)

1 ML satralizumab-mwge 120 MG/ML Prefilled Syringe [Enspryng]

NO BLACK BOX WARNING

Dosage & administration

* Hepatitis B virus, tuberculosis, and liver transaminase screening is required before the first dose.
* Prior to every use, determine if there is an active infection.
* The recommended loading dosage of ENSPRYNG for the first three administrations is 120 mg by subcutaneous injection at Weeks 0, 2, and 4, followed by a maintenance dosage of 120 mg every 4 weeks.
* See Full Prescribing Information for important preparation and administration instructions.

Enspryng prescribing information

Have more Enspryng questions?

Submit MSL Request

Learn More

Need to report an Enspryng issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Enspryng Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Enspryng Start Form

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Enspryng Financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Enspryng Start Form

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Genentech Patient Assistance Program Application - Online, Prescriber Form

Genentech Patient Assistance Program Application - Online, Patient Consent Form

Genentech Patient Assistance Program Application - PDF, Prescriber Form

Genentech Patient Assistance Program Application - PDF, Patient Consent Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Enspryng Patient education

Getting started on Enspryng

Instructions For Use - Neuromyelitis Optica Spectrum Disorder (NMOSD)

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient toolkit

About Enspryng

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Stories

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Patient Resources

ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

Learn More

Enspryng FAQs

Is there a pregnancy exposure registry for ENSPRYNG?Yes, there is a pregnancy exposure registry for ENSPRYNG that monitors pregnancy outcomes in women exposed to the drug during pregnancy. Healthcare providers are encouraged to register patients, and pregnant women are encouraged to register themselves by calling 1-833-277-9338.

What is the risk of using ENSPRYNG during pregnancy?There are no adequate data on the developmental risk associated with the use of ENSPRYNG in pregnant women. In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

Is satralizumab-mwge present in human milk?No information is available on the presence of satralizumab-mwge in human milk. Satralizumab-mwge was excreted in the milk of lactating monkeys administered satralizumab-mwge throughout pregnancy. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ENSPRYNG and any potential adverse effects on the breastfed infant from ENSPRYNG or from the underlying maternal condition.

Is ENSPRYNG safe and effective for use in pediatric patients?Safety and effectiveness in pediatric patients have not been established.

Are there any specific considerations for dosing ENSPRYNG in elderly patients?Clinical studies of ENSPRYNG did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. In general, caution should be used when dosing the elderly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant diseases or other drug therapy.

FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:

Please note:

Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
Samples are provided at the discretion of the brand.
We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.

Enspryng

Dosage & administration

Most viewed Enspryng resources

drug label

Enspryng prescribing information

Have more Enspryng questions?

Need to report an Enspryng issue?

prior authorization

Enspryng Prior authorization resources

Benefits investigation

Reimbursement help (FRM)

financial assistance

Enspryng Financial assistance options

Co-pay savings program

Overview

Patient benefit

Patient eligibility

How to sign up

Bridge program

Overview

Patient benefit

Patient eligibility

How to sign up

Foundation programs

Overview

Patient benefit

Patient eligibility

How to sign up

patient education

Enspryng Patient education

Getting started on Enspryng

Patient toolkit

people also ask

Enspryng FAQs

Can't find what you're looking for?